{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:35:46Z","timestamp":1762508146940},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.urology.2020.05.066","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T15:23:30Z","timestamp":1591975410000},"page":"28-37","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives"],"prefix":"10.1016","volume":"144","author":[{"given":"Muhannad","family":"Alsyouf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Pierorazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Groegler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2020.05.066_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2020.05.066_bib0002","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","article-title":"Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0003","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.eururo.2014.08.003","article-title":"Conditional survival after radical nephroureterectomy for upper tract carcinoma","volume":"67","author":"Ploussard","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0004","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2012.02.030","article-title":"Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature","volume":"62","author":"Lughezzani","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.juro.2007.03.028","article-title":"A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study","volume":"178","author":"Fradet","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2018.04.013","article-title":"Blue light cystoscopy for the diagnosis of bladder cancer: results from the US prospective multicenter registry","volume":"36","author":"Daneshmand","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2020.05.066_bib0007","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.urolonc.2016.11.019","article-title":"Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: safety and feasibility","volume":"35","author":"Donin","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2020.05.066_bib0008","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1016\/j.clgc.2018.01.015","article-title":"An analysis of staging and treatment trends for upper tract urothelial carcinoma in the national cancer database","volume":"16","author":"Browne","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urology.2020.05.066_bib0009","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","article-title":"European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2017 update","volume":"73","author":"Roupret","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.urology.2020.05.066_bib0011","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/089277903322518662","article-title":"Tissue chemoablation","volume":"17","author":"Rehman","year":"2003","journal-title":"J Endourol"},{"key":"10.1016\/j.urology.2020.05.066_bib0012","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11934-018-0827-7","article-title":"Role of angio-embolization for renal cell carcinoma","volume":"19","author":"Gunn","year":"2018","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urology.2020.05.066_bib0013","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2010.08.031","article-title":"Intravesical drug delivery: challenges, current status, opportunities and novel strategies","volume":"148","author":"GuhaSarkar","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.urology.2020.05.066_bib0014","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2016.11.031","article-title":"Urothelium-adherent, ion-triggered liposome-in-gel system as a platform for intravesical drug delivery","volume":"245","author":"GuhaSarkar","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.urology.2020.05.066_bib0015","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.urology.2016.09.039","article-title":"Sustained-release formulation of mitomycin C to the upper urinary tract using a thermosensitive polymer: a preclinical study","volume":"99","author":"Donin","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.05.066_bib0016","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1039\/C8BM01317A","article-title":"Gradiently degraded electrospun polyester scaffolds with cytostatic for urothelial carcinoma therapy","volume":"7","author":"Wang","year":"2019","journal-title":"Biomater Sci"},{"key":"10.1016\/j.urology.2020.05.066_bib0017","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijpharm.2016.08.061","article-title":"Drug-eluting biodegradable ureteral stent: new approach for urothelial tumors of upper urinary tract cancer","volume":"513","author":"Barros","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.urology.2020.05.066_bib0018","first-page":"1794","article-title":"Endoscopic ethanol injection treatment for bladder cancer","volume":"33","author":"Hata","year":"1987","journal-title":"Hinyokika Kiyo"},{"key":"10.1016\/j.urology.2020.05.066_bib0019","first-page":"244","article-title":"Ethanol sclerotherapy in superficial bladder tumors","volume":"30","author":"Damyanov","year":"1996","journal-title":"Ann Urol (Paris)"},{"key":"10.1016\/j.urology.2020.05.066_bib0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00005392-200102000-00011","article-title":"The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder","volume":"165","author":"Mack","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0021","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1200\/JCO.1988.6.3.476","article-title":"Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study","volume":"6","author":"Torti","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2020.05.066_bib0022","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0022-5347(17)54246-9","article-title":"Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients","volume":"127","author":"Prout","year":"1982","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0023","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-5347(01)66552-2","article-title":"Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer","volume":"155","author":"Maffezzini","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0024","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.euo.2018.08.032","article-title":"Chemoablation with intensive intravesical mitomycin C treatment: a new approach for non-muscle-invasive bladder cancer","volume":"2","author":"Racioppi","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urology.2020.05.066_bib0025","doi-asserted-by":"crossref","DOI":"10.1111\/bju.15038","article-title":"CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer","author":"Mostafid","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.05.066_bib0026","first-page":"4912","article-title":"Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies","volume":"59","author":"Di Stasi","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2020.05.066_bib0027","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/jps.2600780505","article-title":"Iontophoretic delivery of model inorganic and drug ions","volume":"78","author":"Phipps","year":"1989","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.urology.2020.05.066_bib0028","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0029","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(11)70190-5","article-title":"Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial","volume":"12","author":"Di Stasi","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urology.2020.05.066_bib0030","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0090-4295(97)00625-0","article-title":"Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study","volume":"51","author":"Brausi","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.05.066_bib0031","first-page":"324","article-title":"Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study","volume":"73","author":"Decaestecker","year":"2018","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.urology.2020.05.066_bib0032","first-page":"199","volume":"29","author":"Van der Meijden","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2017.02.883","article-title":"The chemoblative effect of VesiGel instillation in patient with NMIBC - response rate and 1-year durability [abstract]","author":"Lenis A","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0034","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2004.05.001","article-title":"Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC)","volume":"46","author":"Gontero","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2004.08.027","article-title":"Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions","volume":"65","author":"Serretta","year":"2005","journal-title":"Urology"},{"issue":"3c","key":"10.1016\/j.urology.2020.05.066_bib0036","first-page":"2381","article-title":"Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability","volume":"25","author":"Campodonico","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urology.2020.05.066_bib0037","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.eururo.2006.08.038","article-title":"Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder","volume":"51","author":"Maffezzini","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0038","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.urology.2005.03.084","article-title":"Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder","volume":"66","author":"Gardmark","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.05.066_bib0039","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000331727","article-title":"Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study","volume":"87","author":"Brausi","year":"2011","journal-title":"Urol Int"},{"issue":"4 Pt 1","key":"10.1016\/j.urology.2020.05.066_bib0040","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.juro.2006.06.007","article-title":"Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response","volume":"176","author":"van der Heijden","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0041","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00345-009-0382-4","article-title":"Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer","volume":"27","author":"Hendricksen","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0042","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1464-410X.1994.tb16585.x","article-title":"Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin","volume":"74","author":"Popert","year":"1994","journal-title":"Br J Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0043","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000473784","article-title":"Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group","volume":"29","author":"Bono","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.05.066_bib0044","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000493159","article-title":"Value of a marker lesion in non-muscle-invasive bladder cancer patients treated with Interleukin-2 instillations: a randomized controlled multicentre trial","volume":"102","author":"Bosschieter","year":"2019","journal-title":"Urol Int"},{"key":"10.1016\/j.urology.2020.05.066_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30147-9","article-title":"Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial","author":"Kleinmann","year":"2020","journal-title":"Lancet Oncol"},{"year":"2020","series-title":"Bladder Cancer Guidelines","key":"10.1016\/j.urology.2020.05.066_bib0046"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520306701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520306701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T10:53:05Z","timestamp":1722682385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429520306701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":46,"alternative-id":["S0090429520306701"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2020.05.066","relation":{},"ISSN":["0090-4295"],"issn-type":[{"type":"print","value":"0090-4295"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2020.05.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}